Boston Scientific (NYSE:BSX) Given New $45.00 Price Target at Barclays

Boston Scientific (NYSE:BSX) had its target price lowered by Barclays from $48.00 to $45.00 in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has an equal weight rating on the medical equipment provider’s stock.

BSX has been the subject of a number of other research reports. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Evercore lowered their price target on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating on the stock in a report on Wednesday, October 7th. BTIG Research dropped their price target on shares of Boston Scientific from $56.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday. The Goldman Sachs Group reduced their price objective on shares of Boston Scientific from $71.00 to $57.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. Finally, Wells Fargo & Company decreased their price objective on shares of Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating for the company in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $61.43.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $41.93 on Friday. The stock has a market capitalization of $60.77 billion, a P/E ratio of 13.38, a P/E/G ratio of 1.05 and a beta of 0.58. The business has a 50-day moving average of $44.78 and a two-hundred day moving average of $56.88. Boston Scientific has a fifty-two week low of $39.57 and a fifty-two week high of $105.65. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting analysts’ consensus estimates of $0.73. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the firm posted $0.75 EPS. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. On average, equities research analysts predict that Boston Scientific will post 3.17 EPS for the current fiscal year.

Insider Activity

In other Boston Scientific news, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director directly owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael F. Mahoney bought 186,240 shares of the stock in a transaction on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 189,522 shares of company stock valued at $9,157,810 in the last three months. 0.34% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific during the 1st quarter valued at $28,000. Cassaday & Co Wealth Management LLC bought a new stake in Boston Scientific in the 1st quarter valued at $32,000. Measured Wealth Private Client Group LLC boosted its holdings in Boston Scientific by 244.9% in the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 387 shares during the period. Kelleher Financial Advisors acquired a new stake in Boston Scientific in the 2nd quarter worth $25,000. Finally, Nvwm LLC grew its position in Boston Scientific by 526.2% in the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 542 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.